IGHV status significantly influences CLL prognosis, with mutated IGHV linked to longer survival and unmutated IGHV to shorter progression-free survival. NGS enhances IGHV analysis by overcoming Sanger ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

The most commonly used staging systems worldwide are Rai and Binet, since both are both simple, inexpensive, and easy to use. Staging systems cannot differentiate individuals who will have progressive ...

The BCR IGH is coded for by multiple genes, including VDJ genes. Only productive and functional IG rearrangements are retained in B-cells. IGH gene rearrangements in B-cells undergo additional somatic ...

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin The advent of novel small molecule therapy ...

Chronic lymphocytic leukemia (CLL) is typically a disease of the elderly, but not exclusively. It does occasionally strike younger patients. In the U.S., the median age of individuals at diagnosis is ...

Fixed-duration regimens of venetoclax combined with obinutuzumab (VO) or ibrutinib (VI) show efficacy similar to that of continuous ibrutinib monotherapy in the first-line treatment of chronic ...